Cellebrite DI (NASDAQ:CLBT) Sets New 52-Week Low – Time to Sell?

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) reached a new 52-week low during trading on Thursday . The stock traded as low as $10.55 and last traded at $10.1960, with a volume of 908842 shares changing hands. The stock had previously closed at $15.25.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Needham & Company LLC lowered their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 15th. DA Davidson raised their price objective on Cellebrite DI from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Cellebrite DI has a consensus rating of “Moderate Buy” and an average price target of $21.80.

Cellebrite DI Price Performance

The stock has a market cap of $2.42 billion, a PE ratio of 34.76, a price-to-earnings-growth ratio of 1.99 and a beta of 1.18. The business has a 50 day moving average price of $14.59 and a two-hundred day moving average price of $14.09.

Insider Activity at Cellebrite DI

In related news, CRO Marcus Jewell sold 12,658 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the sale, the executive directly owned 440,101 shares in the company, valued at $5,620,089.77. This represents a 2.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO David Barter sold 41,734 shares of the stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total transaction of $683,602.92. Following the sale, the chief financial officer directly owned 334,219 shares of the company’s stock, valued at $5,474,507.22. The trade was a 11.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 157,810 shares of company stock worth $2,475,185 in the last three months. 5.70% of the stock is owned by insiders.

Institutional Trading of Cellebrite DI

Institutional investors have recently modified their holdings of the company. Elevation Wealth Partners LLC bought a new stake in shares of Cellebrite DI in the second quarter worth about $44,000. Moody National Bank Trust Division raised its position in Cellebrite DI by 7.6% during the 2nd quarter. Moody National Bank Trust Division now owns 60,691 shares of the company’s stock valued at $886,000 after purchasing an additional 4,284 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in Cellebrite DI by 91.1% in the 1st quarter. Pacer Advisors Inc. now owns 7,607 shares of the company’s stock worth $105,000 after buying an additional 3,626 shares during the period. Alpine Woods Capital Investors LLC purchased a new stake in Cellebrite DI in the 1st quarter worth approximately $223,000. Finally, Evolutionary Tree Capital Management LLC grew its position in shares of Cellebrite DI by 22.6% in the 1st quarter. Evolutionary Tree Capital Management LLC now owns 183,473 shares of the company’s stock worth $2,528,000 after buying an additional 33,829 shares during the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.